<p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家在微创微波消融（MWA）技术领域的市场领导者，今天宣布与来自新西兰的全资综合投资管理企业 Stonewood Key Capital 建立战略合作伙伴关系。这一合作将海南自由贸易港定位为公司跨境运营和供应链的关键枢纽，从而实现更高效的资本配置，加速其先进医疗解决方案在全球的商业化。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg"/></p>
<p>在正式签署仪式上，这项协议巩固了 Baird Medical 的市场领导地位，并成为其增长战略的基石。通过利用自由贸易港在跨境资本流动和人员流动方面的有利政策，公司确保了一个旨在满足对微创治疗需求日益增长的竞争性运营框架，特别是针对甲状腺及其他软组织应用。</p>
<p>该合作利用了该地区集成的 “资本 - 基础 - 服务” 生态系统，使 Baird Medical 能够在更广泛的医疗保健领域深化其影响力。</p>
<p>“这项合作代表了我们全球愿景的延伸，而不仅仅是地理上的扩展，” Baird Medical 董事长吴海梅女士表示。“通过将自由贸易港定位为连接供应链韧性与医疗创新的关键枢纽，我们正在扩展我们的能力，以推动全球临床卓越。我们始终专注于赋能医生，改善寻求高质量微创护理的患者的治疗效果。”</p>
<p><strong>关于 Baird Medical</strong></p>
<p>Baird Medical 是一家前瞻性的医疗设备公司，专注于微创诊断和治疗。公司致力于外科机器人系统和创新微创外科器械的研发。我们的使命是通过精确技术和先进的诊断解决方案提升患者的治疗效果。公司将与领先的学术机构建立战略合作关系。我们的愿景超越外科辅助，旨在开发智能系统，主动指导诊断决策和预防医疗策略。作为一家获得 FDA 510(k) 认证的医疗设备公司，Baird Medical 的解决方案已在美国超过 30 家知名医院和诊所中使用，包括梅奥诊所、图兰大学医学中心、哥伦比亚大学医学中心、加州大学旧金山分校医学中心、威尔康奈尔医学中心和乔治华盛顿大学医院。Baird Medical 在中国的甲状腺微波消融设备和耗材市场也处于领先地位。同时，公司的微创治疗产品正在逐步扩大在全球 20 多个国家的商业存在。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含某些不是历史事实的声明，而是根据 1995 年美国私人证券诉讼改革法案的安全港条款的前瞻性声明。前瞻性声明通常与未来事件或 Baird Medical 未来的财务或运营表现相关。在某些情况下，您可以通过诸如 “可能”、“可以”、“应该”、“期望”、“打算”、“可能”、“将”、“估计”、“预期”、“相信”、“预算”、“预测”、“打算”、“计划”、“潜在”、“预测” 或 “继续” 等术语，或这些术语的否定形式或变体或类似术语来识别前瞻性声明。前瞻性声明受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与这些前瞻性声明所表达或暗示的结果有实质性差异。这些前瞻性声明基于 Baird Medical 及其管理层认为合理的估计和假设，但本质上是不确定的。新的风险和不确定性可能会不时出现，无法预测所有风险和不确定性。您不应对本新闻稿中的前瞻性声明过于依赖，这些声明仅在作出时有效，并且完全受限于此处的警示声明。Baird Medical 不承担更新这些前瞻性声明的任何义务。</p>
<p>实际结果可能因多种因素而与前瞻性声明所表达或暗示的结果有实质性差异，包括但不限于：（1）Baird Medical 在中国或美国扩展业务可能不成功的风险；（2）一般经济条件的变化；（3）监管条件和发展；（4）适用法律或法规的变化；（5）对 Baird Medical 或其他人提起的待决和未来诉讼及其他法律程序的性质、成本和结果；以及（6）在与业务合并和过渡报告相关的注册声明中不时描述的其他风险和不确定性，包括在标题为 “风险因素” 的部分中列出的风险，以及 ExcelFin 向 SEC 的其他文件。</p>
<p>上述因素列表并不排他。有关这些及其他风险因素的更多信息，请参阅 ExcelFin 最近向美国证券交易委员会（SEC）提交的文件，以及 Baird Medical 在与 ExcelFin 的业务合并中提交的注册声明。所有后续书面和口头的前瞻性陈述，涉及 Baird Medical、本文所述的业务合并或其他归因于 Baird Medical 或其代表的事项，均完全受到上述警示性声明的限制。读者被提醒不要对任何前瞻性陈述过度依赖，这些陈述仅在作出时有效。Baird Medical 明确声明不承担任何义务或承诺，公开发布任何前瞻性陈述的更新或修订，以反映其预期的任何变化或任何基于的事件、条件或情况的变化。</p>
<p><strong>联系方式：</strong> Eric Huang，公关联络人</p>
<p>Baird Medical Investment Holdings Ltd.</p>
<p>电话：+1 (888) 508-6228</p>
<p>电子邮件：ir@bairdmed.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>来源 BDMD</p>

美国医药设备 ETF - iShares

BDMD

标普健康医疗设备 ETF - SPDR

<p>Baird Medical Investment Holdings Ltd.（纳斯达克代码：BDMD）宣布与 Stonewood Key Capital 建立战略合作伙伴关系，以增强其在微创微波消融技术的全球商业化努力。此次合作将利用海南自由贸易港优化资本配置，增强 Baird Medical 的市场地位。该合作旨在通过扩大对先进医疗解决方案的获取来改善医疗结果。Baird Medical 因其创新的外科手术器械而受到认可，并在美国和中国拥有重要的市场份额</p>

<p>, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (&#34;Baird Medical&#34; or the &#34;Company&#34;), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced a strategic partnership with Stonewood Key Capital, a wholly-owned comprehensive investment management enterprise from New Zealand. This collaboration positions the Hainan Free Trade Port as a pivotal hub for the Company's cross-border operations and supply chain, enabling more efficient capital allocation to accelerate the commercialization of its advanced medical solutions globally.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家在微创微波消融（MWA）技术领域的市场领导者，今天宣布与来自新西兰的全资综合投资管理企业 Stonewood Key Capital 建立战略合作伙伴关系。这一合作将海南自由贸易港定位为公司跨境运营和供应链的关键枢纽，从而实现更高效的资本配置，加速其先进医疗解决方案在全球的商业化。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg" alt="" original-src="https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg"/></p>
<p>Formalized at an official signing ceremony, this agreement reinforces Baird Medical's market leadership and serves as a cornerstone of its growth strategy. By capitalizing on the Free Trade Port's advantageous policies regarding cross-border capital flows and personnel mobility, the Company secures a competitive operational framework designed to meet rising demand for minimally invasive therapies addressing thyroid and other soft tissue applications.</p>
<div class="lb-trans"><p>在正式签署仪式上，这项协议巩固了 Baird Medical 的市场领导地位，并成为其增长战略的基石。通过利用自由贸易港在跨境资本流动和人员流动方面的有利政策，公司确保了一个旨在满足对微创治疗需求日益增长的竞争性运营框架，特别是针对甲状腺及其他软组织应用。</p>
</div><p>The partnership utilizes the region's integrated &#34;Capital – Base-Service&#34; ecosystem, empowering Baird Medical to deepen its footprint in the broader healthcare sector.</p>
<div class="lb-trans"><p>该合作利用了该地区集成的 “资本 - 基础 - 服务” 生态系统，使 Baird Medical 能够在更广泛的医疗保健领域深化其影响力。</p>
</div><p>&#34;This partnership represents an extension of our global vision rather than a mere geographic expansion,&#34; said Mrs. Haimei Wu, Chairwoman of Baird Medical. &#34;By positioning the Free Trade Port as a critical pivot point connecting supply chain resilience with medical innovation, we are expanding our capabilities to drive clinical excellence worldwide. Our focus remains steadfast on empowering physicians and improving outcomes for patients seeking high-quality, minimally invasive care.&#34;</p>
<div class="lb-trans"><p>“这项合作代表了我们全球愿景的延伸，而不仅仅是地理上的扩展，” Baird Medical 董事长吴海梅女士表示。“通过将自由贸易港定位为连接供应链韧性与医疗创新的关键枢纽，我们正在扩展我们的能力，以推动全球临床卓越。我们始终专注于赋能医生，改善寻求高质量微创护理的患者的治疗效果。”</p>
</div><p><strong>About Baird Medical</strong></p>
<div class="lb-trans"><p><strong>关于 Baird Medical</strong></p>
</div><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p>
<div class="lb-trans"><p>Baird Medical 是一家前瞻性的医疗设备公司，专注于微创诊断和治疗。公司致力于外科机器人系统和创新微创外科器械的研发。我们的使命是通过精确技术和先进的诊断解决方案提升患者的治疗效果。公司将与领先的学术机构建立战略合作关系。我们的愿景超越外科辅助，旨在开发智能系统，主动指导诊断决策和预防医疗策略。作为一家获得 FDA 510(k) 认证的医疗设备公司，Baird Medical 的解决方案已在美国超过 30 家知名医院和诊所中使用，包括梅奥诊所、图兰大学医学中心、哥伦比亚大学医学中心、加州大学旧金山分校医学中心、威尔康奈尔医学中心和乔治华盛顿大学医院。Baird Medical 在中国的甲状腺微波消融设备和耗材市场也处于领先地位。同时，公司的微创治疗产品正在逐步扩大在全球 20 多个国家的商业存在。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as &#34;may&#34;, &#34;could&#34;, &#34;should&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;might&#34;, &#34;will&#34;, &#34;estimate&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;budget&#34;, &#34;forecast&#34;, &#34;intend&#34;, &#34;plan&#34;, &#34;potential&#34;, &#34;predict&#34;, or &#34;continue&#34;, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含某些不是历史事实的声明，而是根据 1995 年美国私人证券诉讼改革法案的安全港条款的前瞻性声明。前瞻性声明通常与未来事件或 Baird Medical 未来的财务或运营表现相关。在某些情况下，您可以通过诸如 “可能”、“可以”、“应该”、“期望”、“打算”、“可能”、“将”、“估计”、“预期”、“相信”、“预算”、“预测”、“打算”、“计划”、“潜在”、“预测” 或 “继续” 等术语，或这些术语的否定形式或变体或类似术语来识别前瞻性声明。前瞻性声明受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与这些前瞻性声明所表达或暗示的结果有实质性差异。这些前瞻性声明基于 Baird Medical 及其管理层认为合理的估计和假设，但本质上是不确定的。新的风险和不确定性可能会不时出现，无法预测所有风险和不确定性。您不应对本新闻稿中的前瞻性声明过于依赖，这些声明仅在作出时有效，并且完全受限于此处的警示声明。Baird Medical 不承担更新这些前瞻性声明的任何义务。</p>
</div><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled &#34;Risk Factors&#34; therein, and in ExcelFin's other filings with the SEC.</p>
<div class="lb-trans"><p>实际结果可能因多种因素而与前瞻性声明所表达或暗示的结果有实质性差异，包括但不限于：（1）Baird Medical 在中国或美国扩展业务可能不成功的风险；（2）一般经济条件的变化；（3）监管条件和发展；（4）适用法律或法规的变化；（5）对 Baird Medical 或其他人提起的待决和未来诉讼及其他法律程序的性质、成本和结果；以及（6）在与业务合并和过渡报告相关的注册声明中不时描述的其他风险和不确定性，包括在标题为 “风险因素” 的部分中列出的风险，以及 ExcelFin 向 SEC 的其他文件。</p>
</div><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>
<div class="lb-trans"><p>上述因素列表并不排他。有关这些及其他风险因素的更多信息，请参阅 ExcelFin 最近向美国证券交易委员会（SEC）提交的文件，以及 Baird Medical 在与 ExcelFin 的业务合并中提交的注册声明。所有后续书面和口头的前瞻性陈述，涉及 Baird Medical、本文所述的业务合并或其他归因于 Baird Medical 或其代表的事项，均完全受到上述警示性声明的限制。读者被提醒不要对任何前瞻性陈述过度依赖，这些陈述仅在作出时有效。Baird Medical 明确声明不承担任何义务或承诺，公开发布任何前瞻性陈述的更新或修订，以反映其预期的任何变化或任何基于的事件、条件或情况的变化。</p>
</div><p><strong>Contact:</strong> Eric Huang, PR Liaison</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Eric Huang，公关联络人</p>
</div><p>Baird Medical Investment Holdings Ltd.</p>
<div class="lb-trans"><p>Baird Medical Investment Holdings Ltd.</p>
</div><p>Phone: +1 (888) 508-6228</p>
<div class="lb-trans"><p>电话：+1 (888) 508-6228</p>
</div><p>Email: ir@bairdmed.com</p>
<div class="lb-trans"><p>电子邮件：ir@bairdmed.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>SOURCE BDMD</p>
<div class="lb-trans"><p>来源 BDMD</p>
</div>

Baird Medical 通过与 Stonewood Key Capital 的战略合作加速其全球商业计划 | BDMD 股票新闻